JPRN-UMIN000011949招募中未知
Dysregulation of iron and renal anemia treatment in patients with chronic kidney disease - DIRAT-2 study
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 95years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •malignancy and inflammatory, gastro-intestinal, hepatic, and bone marrow diseases
研究者
相似试验
已完成
不适用
Dysregulation of Iron and Ranal Anemia Treatment in patients with chronic kidney diseaseChronic kidney diseaseJPRN-UMIN000006833Hyogo College of Medicine250
已完成
不适用
An influence of Treatment of Renal Anemia on Iron Dysregulation in patients with chronic kidney diseasechronic kidney disease (CKD)JPRN-UMIN000004136Hyogo College of Medicine50
已完成
4 期
Effects of iron deficiency and its treatment on fibroblast growth factor 23 (FGF23) in patients treated with chronic haemodialysis therapy.ACTRN12614000548639Eastern Health Integrated Renal Service40
尚未招募
Unknown
Iron deficiency in sickle cell diseaseCTRI/2024/01/061216ICMR
进行中（未招募）
1 期
TREAT STUDY : TREATMENT OF IRON DEFICIENCY ANAEMIA WITH TARDYFERON. Importance of prolonging iron supplementation in anemic women of childbearing age - TREAT STUDYIron Deficiency Anaemia is a common pathology which concerns less than 5% of women aged 15 to 49 years old in the western countries but can affect up to 30% of the world population, knowing that 9 to 10 anaemic patients live in developing countries. Treating at least 3 months allows to normalize haemoglobin but it is important to carry on the iron treatment in order to fully replenish the iron stores.EUCTR2006-003378-90-FRPIERRE FABRE MEDICAMENT